Berkeley, Calif. — The OpenFold Consortium has added 11 new members as the nonprofit open science initiative expands its work on open-source AI tools for biology and drug discovery.
The new members are Absci, Adaptive Biotechnologies, Benchling, Chemical Computing Group, Daiichi Sankyo, Flagship Pioneering, Kiin Bio, Nanome, Nxera Pharma, Pledge Therapeutics and Superluminal Medicines.
The consortium said the additions broaden its network of academic and industry collaborators working to build and share open AI models for biological research and drug discovery. OpenFold has released open-source models for structural biology, with recent work focused on next-generation systems for proteins, nucleic acids and small molecules.
“OpenFold is becoming shared infrastructure for the next generation of AI-enabled drug discovery,” said Woody Sherman, chair of the OpenFold Consortium Executive Committee. “This new group of members reflects the breadth of the ecosystem now building on open biomolecular AI: therapeutic discovery, antibody design, GPCR structure-based design, scientific software, data infrastructure, and immersive molecular visualization. Their participation strengthens our ability to build open, auditable, and extensible models that the entire field can use, test, and improve.”
OpenFold said AI-based structure prediction is becoming an increasingly important tool in biology and drug discovery, though many difficult challenges remain. The consortium said its next focus is building open and extensible models that go beyond static structure prediction to support molecular recognition, protein design, antibody-antigen modeling, small-molecule interactions and drug discovery workflows.
The new members expand OpenFold’s community across therapeutic discovery, antibody design, GPCR biology, scientific software, molecular visualization and AI-enabled research infrastructure.
Absci, based in Vancouver, Wash., is a clinical-stage biotech company developing a generative AI platform for therapeutic antibody design. The company is working with OpenFold to advance open methods for drug design, particularly antibodies.
“We’ve been delighted to work with the OpenFold team and support their efforts to achieve state-of-the-art performance on antibody-antigen folding,” said Amir Shanehsazzadeh, chief AI officer of Absci.
Adaptive Biotechnologies, based in Seattle, is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune system into clinical products to diagnose and treat disease.
“Adaptive Biotechnologies is excited to be joining the OpenFold Consortium and to support the development of open-source models of biomolecular structure and interaction. These models will lay the foundation for further breakthroughs in understanding the adaptive immune system and harnessing its power in both diagnostics and therapeutics,” said Harlan Robins, chief scientific officer and co-founder.
Benchling, based in San Francisco, is an AI platform for biotech research and development used by more than 1,300 biotech companies, including more than half of the world’s top 50 biopharma companies. Through its Model Hub, scientists can discover, run and track predictive models, including OpenFold2 and OpenFold3-preview, inside their research workflows.
Chemical Computing Group, based in Montreal, provides the Molecular Operating Environment, or MOE, drug discovery software platform for visualization, modeling, simulations and methodology development.
Daiichi Sankyo, headquartered in Tokyo, is a global healthcare company focused on oncology and other areas, including an antibody drug conjugate portfolio and new technologies for drug development.
Flagship Pioneering, based in Cambridge, Mass., is a scientific innovation company that creates and builds platform companies across human health, sustainability and other fields. The company’s AI platform, Pioneering Intelligence, integrates data, models and agentic systems across its ecosystem.
Kiin Bio, based in London, provides a collaborative platform for scientists and teams to execute experiments, connect insights and accelerate decisions from target to clinic.
“Drug discovery slows down when insight gets stuck between teams and tools,” said Filippo Abbondanza, CEO of Kiin Bio. “The models everyone builds on should be open, benchmarked and interconnected.”
Nanome, based in San Diego, provides molecular visualization and collaboration tools across web, AR/VR devices and traditional displays.
“We’re excited to bring more structures to people through our partnership with OpenFold,” said Steve McCloskey, CEO of Nanome. “Researchers around the world can now rapidly work together with predictive protein structures in greater detail than ever before. Advances in structure prediction, simulation, and immersive interfaces are fundamentally changing how research is done, making complex molecular insight more accessible, collaborative, and actionable.”
Nxera Pharma, headquartered in Tokyo, is a technology-powered biopharma company focused on GPCR structure-based drug design. Its NxWave platform combines structural biology with AI-driven computational chemistry and quantum-inspired physics approaches.
Pledge Therapeutics, based in Canton, Mass., is a preclinical drug discovery company developing models designed to learn the physics and energetics of molecular interactions. The company said OpenFold’s emphasis on accuracy, interpretability and transparency aligns with its approach to AI-driven drug discovery.
Superluminal Medicines is a drug discovery company developing small-molecule oral therapies targeting GPCRs. Its Hyperloop Platform integrates generative AI, machine learning and structural biology to model dynamic protein conformations and support drug discovery.
